共 47 条
- [1] Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS studyJOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):MaassenVanDenBrink, AntoinetteTerwindt, Gisela M.Cohen, Joshua M.Barash, SteveCampos, Verena RamirezGalic, MajaNing, XiaopingKarppa, Mikko
- [2] Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trialJOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):Spierings, Egilius L. H.Karppa, MikkoNing, XiaopingCohen, Joshua M.Campos, Verena RamirezYang, RonghuaReuter, Uwe
- [3] Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trialThe Journal of Headache and Pain, 2021, 22Egilius L. H. SpieringsMikko KärppäXiaoping NingJoshua M. CohenVerena Ramirez CamposRonghua YangUwe Reuter
- [4] Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS studyThe Journal of Headache and Pain, 2021, 22Messoud AshinaJoshua M. CohenMaja GalicVerena Ramirez CamposSteve BarashXiaoping NingYoel KesslerLindsay JankaHans-Christoph Diener
- [5] Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS studyJOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):Ashina, MessoudCohen, Joshua M.Galic, MajaCampos, Verena RamirezBarash, SteveNing, XiaopingKessler, YoelJanka, LindsayDiener, Hans-Christoph
- [6] Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patientsHEADACHE, 2021, 61 (07): : 1102 - 1111Sakai, FumihikoSuzuki, NorihiroKim, Byung-KunTatsuoka, YoshihisaImai, NoboruNing, XiaopingIshida, MikiNagano, KaoriIba, KatsuhiroKondo, HiroyukiKoga, Nobuyuki
- [7] Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studiesThe Journal of Headache and Pain, 2021, 22Stephanie J. NahasSteffen NaegelJoshua M. CohenXiaoping NingLindsay JankaVerena Ramirez CamposLynda J. KrasenbaumDagny Holle-LeeDavid KudrowChristian Lampl
- [8] Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studiesJOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):Nahas, Stephanie J.Naegel, SteffenCohen, Joshua M.Ning, XiaopingJanka, LindsayCampos, Verena RamirezKrasenbaum, Lynda J.Holle-Lee, DagnyKudrow, DavidLampl, Christian
- [9] Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patientsHEADACHE, 2021, 61 (05): : 755 - 765Sakai, FumihikoTakeshima, TakaoHomma, GosukeTanji, YukaKatagiri, HideakiKomori, Mika
- [10] Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patientsHEADACHE, 2021, 61 (07): : 1092 - 1101Sakai, FumihikoSuzuki, NorihiroKim, Byung-KunIgarashi, HisakaHirata, KoichiTakeshima, TakaoNing, XiaopingShima, TomokoIshida, MikiIba, KatsuhiroKondo, HiroyukiKoga, Nobuyuki